Gary Gintant, Bernard Fermini, Norman Stockbridge, David Strauss
文献索引:10.1016/j.stem.2017.06.005
全文:HTML全文
Nonclinical studies of drug effects with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide new possibilities for evaluating drug safety and efficacy. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm provides lessons from the cardiac field that also apply to drug studies with other stem cell-based assays.
ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Supp...
2017-07-13 [10.1016/j.stem.2017.06.004] |
Lineage Tracing: Papers and Progress
2017-07-06 [10.1016/j.stem.2017.06.015] |
Intestinal Enteroendocrine Lineage Cells Possess Homeostatic...
2017-07-06 [10.1016/j.stem.2017.06.014] |
Direct Neuronal Reprogramming: Achievements, Hurdles, and Ne...
2017-07-06 [10.1016/j.stem.2017.06.011] |
Making HSCs on Demand: Looking Ahead
2017-07-06 [10.1016/j.stem.2017.06.010] |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2024 ChemSrc All Rights Reserved